Synergistic effect of combination treatment of irinotecan and anti-mouse surrogate ABL001 antibodies in GC-bearing mouse model. (A-C) AGS cells (1 × 106) were injected subcutaneously in nude mice (n = 5). Once palpable tumors were detectable, the mice were administrated 200 µl PBS (as control), 3.25 mg/kg ABL 001, 10 mg/kg irinotecan, or a combination of 3.25 mg/kg ABL001 and 10 mg/kg irinotecan by intraperitoneal (i.p.) injection twice a week. (A) Tumor size was measured every week for 5 weeks and presented graphically. (B) At the end of the treatment, the mice were euthanized and tumors were excised and photographed. (C) Tumors were weighed and the results were presented as bar graph. (D-F) Luciferase gene-transfected AGS cells were injected subcutaneously in nude mice and allowed to grow. The palpable tumor was excised and cut into sections of 10 mm3. A section of the tumor was surgically transplanted in the stomach walls of fresh nude mice (n = 5). After establishment of orthotopic gastric tumors, the mice were administered 200 µl PBS (as control), 10 mg/kg irinotecan, or a combination of 3.25 mg/kg ABL001 and 10 mg/kg irinotecan through intraperitoneal (i.p.) injection twice a week for 5 weeks. (D) In vivo bioluminescent imaging of the tumor growth in mice. (B) Mice were euthanized and the orthotopic gastric tumors were excised and photographed. (C) Tumor growth was quantified by measuring the tumor weight and volume and results were presented as graphs. *P < 0.05, **P < 0.01, and *** P < 0.001.
